虫类药物治疗肺纤维化实验研究现状及临床遣方用药思考
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R563

基金项目:

河南省中医药科学研究专项课题(2016ZY2029);国家自然科学基金面上项目(81674098)


Current Situation of Experimental Research of Insect Medicine Treating Pulmonary Fibrosis and Thoughts of Clinical Prescriptions and Medication
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    肺纤维化病机总属本虚标实,肺络瘀阻是促进肺纤维化进展的主要病理机制。通过对近年来虫类药物治疗肺纤维化的实验研究进行分析总结并结合临床,发现水蛭、地龙、蜚蠊,蛤蚧、蜈蚣、蛇、冬虫夏草单味药物或两种及以上虫类药复方最为常用。虫类药物在减少纤维蛋白沉积、减轻炎性细胞浸润,抑制成纤维细胞增长,改善肺血管重塑等方面发挥重要作用。对于肺纤维化的治疗,虫类药物有良好的应用前景,值得进一步深层次研究。

    Abstract:

    Abstract:The pathogenesis of pulmonary fibrosis is generally the deficiency in root and excess in tip,and lung vessels stasis is the main pathological mechanism that promotes the progression of pulmonary fibrosis. Through the analysis and summary of the experimental studies on the treatment of pulmonary fibrosis with insect medicines in recent years and the combination with clinical practice, it is found that the single drug treatment including leech, earth- worm, roach, giant gecko,centipede,snake and Chinese caterpillar fungus,or complex prescription of two or more insect medicines are the most commonly used. Insect medicines play an important role in reducing fibrin deposition, alleviating inflammatory cells infiltration, inhibiting fibroblast growth and improving pulmonary vascular remodeling. For the treatment of pulmonary fibrosis,insect medicines have a good application prospect and deserve further in-depth study.

    参考文献
    相似文献
    引证文献
引用本文

桂吟哲,王至婉,李伟珂,谢洋.虫类药物治疗肺纤维化实验研究现状及临床遣方用药思考[J].新中医,2021,53(9):1-5

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-05-12
  • 出版日期:
文章二维码